ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0569

The Longitudinal Association Between Disease Activity, Function and Health-Related Quality of Life in Axial Spondyloarthritis: Results from the DESIR Cohort

Augusta Ortolan1, Desiree van der Heijde2, Laure Gossec3 and Sofia Ramiro4, 1Policlinico Universitario Agostino Gemelli IRCSS, Rome, Lazio, Italy, 2Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, 3Sorbonne Université, Paris, France, 4Leiden University Medical Center, Bunde, Netherlands

Meeting: ACR Convergence 2024

Keywords: Disease Activity, functional status, quality of life, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Health-related quality of life (HRQoL) in axSpA is considered an overarching outcome, with other disease outcomes contributing to it [1]. To validate a previously proposed model on the relationship between disease outcomes, we aimed to investigate the longitudinal relationship between disease activity and function (independent variables) and HRQoL (outcome).

Methods: AxSpA patients with symptoms< 3 years, enrolled in the DESIR cohort, were included. Outcomes were collected longitudinally up to 10 years. The association between disease activity (ASDAS) and physical function (BASFI), on the one hand, and HRQoL (outcome: SF36-MCS, SF36-PCS, ASQoL) was assessed. SpA features, personal and environmental factors, and therapy were collected at baseline (sex, age, HLA-B27 positivity, MRI/radiographic sacroiliitis) or during follow-up (psoriasis, IBD, uveitis, enthesitis, dactylitis, peripheral arthritis, BMI, smoking, job type, education, marital status, parental status, NSAIDs/bDMARDs use, comorbidities) and tested as confounders or effect modifiers. Generalised estimating equations (GEE) were built with SF36-MCS, SF36-PCS, or ASQoL as outcomes (separate models), and ASDAS and BASFI as main independent variables. Covariates were included in the final multivariable models, conducted both as simple GEE models and autoregressive models (corrected for HRQoL at the previous time point). Results were expressed as beta coefficient (Beta) and 95% confidence interval (95% CI).

Results: A total of 663 axSpA patients (46% males, mean age 33.5 [8.6] years) were included. In simple models including only ASDAS and BASFI as independent variables, significant associations were found with SF36-MCS (Beta -2.43[-2.84,-2.04]; -1.23[-1.43,-1.03]), SF36-PCS (-3.07[-3.32,-2.83]; -2.24[-2.37,-2.11]), and ASQoL (1.35[1.23,1.48]; 1.16[1.09,1.22]). These results were confirmed in autoregressive models: effect sizes for ASDAS and BASFI varied modestly when corrected for relevant confounders (Table).

Conclusion: A longitudinal relationship between disease activity and function, on the one hand, and HRQoL as the outcome, has been demonstrated, confirming that HRQoL can be interpreted as an overarching outcome in axSpA.

References. [1] Machado P, et al. Ann Rheum Dis 2011;70:1758-64.

Supporting image 1

Longitudinal association between disease activity, function and health related quality of life.


Disclosures: A. Ortolan: AbbVie/Abbott, 2, Janssen, 2, Novartis, 2, UCB, 1; D. van der Heijde: AbbVie, 2, ArgenX, 2, BMS, 2, Eli Lilly, 2, Galapagos, 2, GSK, 2, Imaging Rheumatology BV, 3, Janssen, 2, Novartis, 2, Pfizer, 2, Takeda, 2, UCB Pharma, 2; L. Gossec: AbbVie, 2, 5, Amgen, 2, Biogen, 5, Bristol-Myers Squibb (BMS), 2, Celltrion, 2, Eli Lilly, 2, 5, Galapagos, 2, Janssen, 2, MSD, 2, Novartis, 2, 5, Pfizer, 2, Sandoz, 2, UCB, 2, 5; S. Ramiro: AbbVie, 1, 2, 5, 6, Alfasigma, 1, 2, 5, Galapagos, 1, 2, 5, Lilly, 1, 2, 6, MSD, 2, 5, 6, Novartis, 1, 2, 5, 6, Pfizer, 1, 2, 5, 6, UCB, 1, 2, 5, 6.

To cite this abstract in AMA style:

Ortolan A, van der Heijde D, Gossec L, Ramiro S. The Longitudinal Association Between Disease Activity, Function and Health-Related Quality of Life in Axial Spondyloarthritis: Results from the DESIR Cohort [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/the-longitudinal-association-between-disease-activity-function-and-health-related-quality-of-life-in-axial-spondyloarthritis-results-from-the-desir-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-longitudinal-association-between-disease-activity-function-and-health-related-quality-of-life-in-axial-spondyloarthritis-results-from-the-desir-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology